Sanofi stock rises 2.29% from November 11 report
Published on 11/12/2026 at 18:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSanofi's next investor milestones
- Sanofi reviewed its third-quarter 2026 results with investors on October 30.
- The company upgraded its full-year 2026 guidance after reporting double-digit sales and business EPS growth.
- Further healthcare conferences are scheduled in London on November 17 and Boston on November 24.
Sanofi stock traded at 88.02 euros on Lang & Schwarz at 18:03:22 CET on Thursday, November 12, 2026. That was 2.29 percent above the 86.05-euro quote in the latest relevant report published on November 11.
What changed for investors
The higher quote gives investors a fresh reference point as Sanofi's recent news flow focuses on pipeline expansion and growth beyond established products. The move also marks a material change from the level cited in the previous report.
Operating backdrop remains central
Sanofi's investor relations page says management reviewed third-quarter 2026 results with the financial community on October 30. The company reported double-digit sales and business EPS growth and upgraded its full-year 2026 guidance, according to the Sanofi investor relations page.
Upcoming investor dates
Sanofi's calendar lists the Jefferies Global Healthcare Conference in London on November 17, followed by the Leerink Partners East Coast conference in Boston on November 24. These events give investors further opportunities to assess management's view on growth, research and business development.
Sanofi stock at a glance
- Company: Sanofi
- ISIN: FR0000120578
- Ticker: SNY
- Home exchange: Euronext Paris
- Lang & Schwarz quote: 88.02 euros at 18:03:22 CET on Thursday, November 12, 2026
- Change from November 11 report: 2.29 percent higher than 86.05 euros
French healthcare shares remain part of the broader market represented by the CAC 40.
For more company developments, see More news and analyses on Sanofi stock.
